摘要:
Structural modifications of the initial lead, 3-aminochroman (4), led to the identification of a novel series of pyridyl-fused amino chroman derivatives (5-8) and the structural isomers (9-12). The compounds described were evaluated for dual 5-HT transporter inhibitory and 5-HT1A receptor activities. The design strategy, synthesis, and in vitro biological characterization for these novel compounds are described. (C) 2007 Elsevier Ltd. All rights reserved.